Use of oral contraceptives and postmenopausal hormone replacement: Evidence on risk of stroke

Current Treatment Options in Neurology

Volumn 10, Issue 6, 2008, Pages 468-474

  Davis, Patricia H ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; PROTHROMBIN;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG WITHDRAWAL; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LOW DRUG DOSE; MIGRAINE WITH AURA; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; OBESITY; POSTMENOPAUSE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; THROMBOPHILIA;

EID: 58649123782     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0049-2     Document Type: Review

References (35)

1. Harman SM: Estrogen replacement in mRnopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med 2006, 3:254-269.
2. Bushnell CD: Oestrogen anA stroke in women: assessment of risk. Lancet Neurol 2005, 4:743-751.
3. Duckles SP, Krause DN: Cerebrovascular effects of oestrogen: multiplicity of action. Clin Exp Pharmacol Physiol 2007, 34:801-808.
4. Billeci A, Paciaroni M, Caso V, Agnelli G: Hormone replacement therapy and stroke. Curr Vasc Pharmacol 2008, 6:112-123.
5. Wierman ME, Kohrt WM: Vascular and metabolic effects of sex steroids: new insights into clinical trials. Reprod Sci 2007, 14:300-314.
6. Manson JE, Bassuk SS, Harman S, et al.: Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006, 13:139-147.
7. Miller VM, Jayachandran M, Hashimoto K, et al.: Estrogen, inflammation, and platelet phenotype. Gend Med 2008, 5(Suppl 1): S91-S102.
8. The ESHRE Capri Workshop Group: Hormones and cardiovascular health in women. Hum Reprod Update 2006, 12:483-497.
9. Hodis HN, Mack WJ: Postmenopausal hormone therapy in clinical perspective. Menopause 2007, 14:944-957.
10. Kemmeren JM, Tanis BC, van den Bosch MA, et al.: Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 2002, 33:1202-1208.
11. Stein DG, Wright DW, Kellermann AL: Does progesterone have neuroprotective properties? Ann Emerg Med 2008, 51:164-172.
12. Chan WS, Ray J, Wai EK, et al.: Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Arch Intern Med 2004, 164:741-747.
13. Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis. J Clin Endocrinol Metab 2005, 90:3863-3870.
14. Gillum LA, Mamidipudi SK, Johnston SC: Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000, 284:72-78.
15. MacClellan LR, Giles W, Cole J, et al.: Probable migraine with visual aura and risk of ischemic stroke: The Stroke Prevention in Young Women Study. Stroke 2007, 38:2438-2445.
16. Slooter AJ, Rosendaal FR, Tanis BC, et al.: Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005, 3:1213-1217.
17. Martinelli I, Battaglioli T, Burgo I, et al.: Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006, 91:844-847.
18. Pezzini A, Grassi M, Iacoviello L, et al.: Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007, 78:271-276.
19. Pruissen DM, Slooter AJ, Rosendaal FR, et al.: Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008, 111: 1282-1286.
20. ACOG Committee on Practice Bulletins-Gynecology: ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006, 107:1453-1472.
21. Goldstein LB, Adams R, Alberts MJ, et al.: Primary prevention of ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council. Stroke 2006, 37:1583-1633.
22. Rosamond W, Flegal K, Furie K, et al.: Heart disease and stroke statistics - 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
23. Bushnell CD: Hormone replacement tTerapy and stroke: the current state of knowledge and directions for future research. Semin Neurol 2006, 26:123-130.
24. Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243-1249.
25. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al.: Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434.
26. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004, 291:1701-1712.
27. Wassertheil-Smoller S, Hendrix S, Limacher M, et al., for the WHI Investigators: Effect of estrogen plus progestin on stroke in postmenopausal women: TheAWomen's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684.
28. Rossouw JE, Prentice RL, Manson JE, et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
29. Manson JE, Allison MA, Rossouw JE, et al.: Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591-2602.
30. Kooperberg C, Cushman M, Hsia J, et al.: Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials 2007, 2:E28.
31. Bath PMW, Gray LJ: Association between hormone replacement therapy and subsequent stroke: A meta-analysis. BMJ 2005, 330:342.
32. Heiss G, Wallace R, Anderson GL, et al.: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008, 299:1036-1045.
33. Grodstein F, Manson JE, Stampfer MJ, Rexrode K: Postmenopausal hormone therapy and stroke: Role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008, 168:861-866.
34. Umland EM: Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008, 14(3 Suppl): S14-S19.
35. Bushnell CD: Stroke and the female brain. Nat Clin Pract Neurol 2008, 4:22-33.